Novartis AG (NYSE:NVS) J.P. Morgan forty third Annual Healthcare Convention January 14, 2025 12:00 PM ET
Firm Contributors
Vas Narasimhan – Chief Govt Officer
Convention Name Contributors
Richard Vosser – J.P. Morgan
Richard Vosser
Welcome to the Novartis presentation on the forty third JPMorgan Healthcare Convention. I am Richard Vosser, European pharma analyst with JPMorgan. It is my nice pleasure to introduce Vas Narasimhan, the CEO of Novartis. Earlier than I hand over to Vas, I would just remind you that there’s a Q&A interval after Vas’s presentation. So, you possibly can both put up your hand or you possibly can submit via the portal, after which we’ll take your questions. Vas, a fantastic welcome to the convention.
Vas Narasimhan
Thanks. Thanks, Richard, and nice to be with all of you as each January. I am excited to provide you an outline of the place Novartis is that this yr, the place we’re headed, significantly from a pipeline standpoint and hopefully get some nice insights and have a very good dialogue with Richard.
Now I believe as lots of you who’ve adopted us know, we have had fairly a metamorphosis during the last decade. Shifting from a extremely diversified well being care conglomerate to a pure-play firm, alongside the best way creating actually out of 1 firm, 4 glorious firms, Haleon Client Well being with GSK; Alcon, a number one medical system firm; Sandoz, a number one generics firm; and now right now 100% targeted Novartis. And alongside that journey, what I believe is commonly misplaced is the sturdy underlying efficiency we have had inside our Progressive Medicines enterprise.
Whenever you take a look at it over that interval, our Progressive Medicines gross sales has grown 7%. Our core op. Inc. has grown 14%. Our margin is up 990 foundation factors on our method to our aim of a 40%-plus core margin. So, we have been capable of — whereas making all of those transformations, redesigning our firm, persevering with to construct on
